Clover Biopharmaceuticals, Ltd. — Form D/A
Clover Biopharmaceuticals, Ltd. of CHENGDU, F4, a company, filed a Form D amendment with the SEC on 2025-04-28. The offering totals $905K, of which $905K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-04-28
- Form: D/A
- Accession: 0001856491-25-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $905K
- Amount sold: $905K
- Investors: 13
- Date of first sale: 2024-04-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-510412
Issuer
- Name: Clover Biopharmaceuticals, Ltd.
- CIK: 0001856491
- Entity type: Corporation
- Jurisdiction: CAYMAN ISLANDS
- Incorporated: 2018
- Address: B5-19,BUILDING,HIGH-TECH INCUBATION PARK NO. 1480 NORTH SECTION OF TIANFU AVENUE, CHENGDU, F4, 610041
- Phone: 0086-28-8533-6966
Officers, directors & promoters (12)
| Name | Role | Location |
|---|
| Joshua Liang | Director | Chengdu, F4 |
| Peng Liang | Director | Chengdu, F4 |
| Xiaodong Wang | Director | Yarrow Point, WA |
| Joshua Liang | Executive Officer | Chengdu, F4 |
| Peng Liang | Executive Officer | Chengdu, F4 |
| Peng Liang | Promoter | Chengdu, F4 |
| Xiaodong Wang | Related Person | Yarrow Point, WA |
| Joshua Liang | Related Person | Chengdu, F4 |
| Peng Liang | Related Person | Chengdu, F4 |
| Guangyu Xu | Director | Beijing, F4 |
| Dong Lyu | Director | Beijing, F4 |
| Ting Xiao | Director | Hong Kong, K3 |
Other filings by this issuer (5)
More